Status:
COMPLETED
Tumor RNA Transfected Dendritic Cell Vaccines
Lead Sponsor:
US Department of Veterans Affairs
Conditions:
Prostate Cancer
Eligibility:
MALE
10+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disse...
Detailed Description
The specific aims are: 1) to evaluate, in a phase I clinical trial, the safety of vaccinating patients with dendritic cells transfected with RNA from autologous cancer cells; 2) to analyze the T cell ...
Eligibility Criteria
Inclusion
- Patients with a histologically confirmed diagnosis of metastatic prostate cancer stages D1 - D3 are eligible for this study.
- They must not have a history of autoimmune disease, serious intercurrent chronic or acute illness, pulmonary disease, active hepatitis, serologic evidence for HIV, or be receiving corticosteroid or immunosuppressive therapy.
Exclusion
- Patients will be excluded from the study if they have received chemotherapy or other forms of immunotherapy in the 6 weeks prior to study entry.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00108264
End Date
September 1 2005
Last Update
January 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Durham VA Medical Center
Durham, North Carolina, United States, 27705